Key facts
- It has raised $43.4M; the latest was Later Stage VC in Sep 2025.
- Notable investors include Cowin Capital, GSR United Capital, HaiBang Ventures, Heda Ventures, Zhuzhou SAH Innovation & Entrepreneur Investment — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for AnDiConBio
- ·The full record, as it builds
Funding rounds
No funding rounds for AnDiConBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AnDiConBio
Developer of drugs designed for respiratory anti-infection. The company has established a product pipeline including a variety of drugs, including new anti-influenza and oral anti-new coronavirus, which have high drug potential and low clinical risks, thereby providing customers with safe and efficient drugs.
- Sector
- Healthcare
- HQ
- Jiaxing, China
- Founded
- 2018
- Employees
- 6
- Website
- andicon.cn/
- Ownership
- Privately Held (backing)
AnDiConBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AnDiConBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AnDiConBio in its N-PORT filings yet. We sweep new filings monthly.